Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.
Drugs. 2015 Dec;75(18):2143-54. doi: 10.1007/s40265-015-0514-7.
Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a solution or tablets) and as an intravenous infusion for use as monotherapy (only in the USA) or adjunctive therapy for the treatment of focal seizures in adult and adolescent (aged ≥17 years in the USA) patients with epilepsy. As adjunctive therapy to other antiepileptic drugs (AEDs), lacosamide provided effective seizure control and was generally well tolerated in adults and adolescents (aged ≥16 years) in randomized clinical trials and in the real-world setting. In clinical trials, adjunctive lacosamide provided significantly greater reductions in 28-day seizure rates than adjunctive placebo, with these benefits maintained after up to 8 years of therapy in open-label extension studies. Moreover, patients were effectively switched from oral to short-term intravenous adjunctive therapy at the same dosage, which may be particularly beneficial in situations where oral therapy is not suitable. Conversion to lacosamide monotherapy was superior to a historical-control cohort in patients with focal seizures converting from previous AED therapy. In the absence of head-to-head comparisons with other AEDs, the exact position of lacosamide relative to other AEDs remains to be fully determined. In the meantime, oral and intravenous lacosamide provides a useful option as monotherapy (only in the USA) or adjunctive therapy for the treatment of focal seizures in adult and adolescent (aged ≥17 years in the USA) patients with epilepsy.
拉考沙胺（Vimpat(®)）是一种可口服（溶液或片剂）和静脉输注的功能性氨基酸，可作为单药治疗（仅在美国）或辅助治疗用于治疗成人和青少年（美国为≥17 岁）癫痫患者的局灶性发作。作为其他抗癫痫药物（AEDs）的辅助治疗药物，拉考沙胺在随机临床试验和真实世界环境中为成人和青少年（≥16 岁）提供了有效的癫痫发作控制，并且通常具有良好的耐受性。在临床试验中，与辅助安慰剂相比，辅助拉考沙胺使 28 天发作率显著降低，在开放标签扩展研究中，这些益处可维持长达 8 年的治疗。此外，患者可以有效地从口服转为短期静脉辅助治疗，而无需调整剂量，这在口服治疗不合适的情况下可能特别有益。与之前的 AED 治疗转换为局灶性发作的患者相比，转换为拉考沙胺单药治疗的疗效优于历史对照队列。由于没有与其他 AED 进行头对头比较，因此拉考沙胺相对于其他 AED 的确切地位仍有待充分确定。在此期间，口服和静脉内拉考沙胺为美国≥17 岁的成人和青少年（美国为≥17 岁）癫痫患者的局灶性发作提供了一种有用的单药治疗（仅在美国）或辅助治疗选择。
